Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

JAMA

Volumn 291, Issue 20, 2004, Pages 2433-2440

  Terry, Mary Beth ^a,b   Gammon, Marilie D ^d   Zhang, Fang Fang ^a   Tawfik, Heba ^a   Teitelbaum, Susan L ^e   Britton, Julie A ^e   Subbaramaiah, Kotha ^b   Dannenberg, Andrew J ^b   Neugut, Alfred I ^a,b,c  

^a Columbia University ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d IL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; AROMATASE; HORMONE RECEPTOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; ADULT; AGED; BREAST TUMOR; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 2442662761     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.20.2433     Document Type: Article

References (32)

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
2. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1-24.
3. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
4. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
5. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97-102.
6. Carter CA, Milholland RJ, Shea W, Ip MM. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res. 1983;43:3559-3562.
7. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56:2556-2560.
8. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer. 2001;8:97-114.
9. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137:5739-5742.
10. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999;140:27-35.
11. Elvin JA, Yan C, Matzuk MM. Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway. Proc Natl Acad Sci U S A. 2000;97:10288-10293.
12. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
13. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med. 1995;24:107-109.
14. Harris RE, Namboodiri K, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 1995;24:119-120.
15. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7:203-205.
16. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71-73.
17. Coogan PF, Rao SR, Rosenberg L, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med. 1999;29:72-76.
18. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83:112-120.
19. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:1213-1217.
20. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1586-1591.
21. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63:6096-6101.
22. Gammon MD, Neugut AI, Santella RM, et al. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat. 2002;74:235-254.
23. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. New York, NY: John Wiley & Sons; 1991.
24. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.
25. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299:1247-1250.
26. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88:988-993.
27. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642-1646.
28. Rosenberg L. Aspirin and breast cancer: no surprises yet. J Natl Cancer Inst. 1996;88:941-942.
29. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
30. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96-102.
31. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265-271.
32. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta analysis. BMJ. 2000;321:1183-1187.